DMAA (1,3-Dimethylamylamine) Powder

The FDA issued a public warning in April 2013 against products containing DMAA specifically because of cardiovascular injury and death risk, and had received 100+ adverse event reports by that point. DMAA is not Generally Recognized As Safe (GRAS) and isn't excluded from the legal definition of "food additive" — a firmer regulatory position than most compounds in this catalog.

1,3-Dimethylamylamine is a stimulant, mechanistically constricting blood vessels and raising heart rate/blood pressure. Human study (n=7, single 25mg oral dose): at this specific low dose, no meaningful change in heart rate (mean 64bpm), blood pressure (118/78 mmHg), or body temperature was measured. Schilling et al., BMC Pharmacol Toxicol, 2013 This is a real tension worth stating plainly: a controlled low-dose study found no measurable cardiovascular effect, while real-world use (often at higher doses, in stacks with other stimulants) generated the adverse event pattern that triggered the FDA warning. Both things are true; the dose and context clearly matter.

Documented in case reports and FDA adverse-event data: elevated blood pressure, shortness of breath, chest tightening, and — in serious cases — myocardial infarction, hemorrhagic stroke, seizures, and stress-induced cardiomyopathy. This is a real, regulator-flagged risk profile, not a theoretical caution.